darifenacine | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Darifenacine
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

darifenacine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

24 API Suppliers, 14 USDMF, 7 EU WC, 7 NDC API, 12 Listed Suppliers, $ API Reference Price

24 API Suppliers
14 USDMF
7 EU WC
7 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

55 FDF Dossiers, 20 FDA Orange Book, 14 Europe, 6 Canada, 5 South Africa, 10 Listed Dossiers

55 FDF Dossiers
20 FDA Orange Book
14 Europe
6 Canada
5 South Africa
10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 5 DKSH, 3 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 9 BASF, 3 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 1 Esteem Industries, 1 Finar, 8 Gangwal Chemicals, 5 Ideal Cures, 21 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 6 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 9 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

45 Coating Systems & Additives, 38 Fillers, Diluents & Binders, 22 Controlled & Modified Release, 18 Thickeners and Stabilizers, 16 Lubricants & Glidants, 15 Topical, 14 Direct Compression, 14 Granulation, 10 Film Formers & Plasticizers, 10 Co-Processed Excipients, 8 Solubilizers, 6 Disintegrants & Superdisintegrants, 6 API Stability Enhancers, 5 Emulsifying Agents, 5 Rheology Modifiers, 5 Parenteral, 5 Empty Capsules, 4 Chewable & Orodispersible Aids, 4 Vegetarian Capsules, 4 Taste Masking, 4 Coloring Agents, 2 Surfactant & Foaming Agents

45 Coating Systems & Additives
38 Fillers, Diluents & Binders
22 Controlled & Modified Release
18 Thickeners and Stabilizers
16 Lubricants & Glidants
15 Topical
14 Direct Compression
14 Granulation
10 Film Formers & Plasticizers
10 Co-Processed Excipients
8 Solubilizers
6 Disintegrants & Superdisintegrants
6 API Stability Enhancers
5 Emulsifying Agents
5 Rheology Modifiers
5 Parenteral
5 Empty Capsules
4 Chewable & Orodispersible Aids
4 Vegetarian Capsules
4 Taste Masking
4 Coloring Agents
2 Surfactant & Foaming Agents

DIGITAL CONTENT

12 News #PharmaBuzz

12 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 10 Regulatory FDF Prices, 2 Annual Reports

6 US Medicaid Prescriptions
10 Regulatory FDF Prices
2 Annual Reports

MARKET PLACE

2 APIs, 4 FDF Dossiers

2 APIs
4 FDF Dossiers

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 Others

4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 4,443 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 2Gowling Lafleur Henderson LLP

02 4Searchlight Pharma Inc.

filter Patent Reset all filters

6 All

01 22230314

02 22469702

03 22480287

filter Product Reset all filters

6 All

01 6Darifenacin Hydrobromide

filter Dosage Reset all filters

6 All

01 6Extended Release Tablet

filter Exp Date Reset all filters

6 All

01 22016-08-21

02 22022-03-05

03 22023-03-17

Product Main Page

01

Gowling Lafleur Henderson LLP

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-08-21

Date Granted : 2003-06-24

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2230314

Filing Date : 1996-08-21

Strength per Unit : 7.5 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-08-21

Date Granted : 2003-06-24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling Lafleur Henderson LLP

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-08-21

Date Granted : 2003-06-24

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2230314

Filing Date : 1996-08-21

Strength per Unit : 15 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-08-21

Date Granted : 2003-06-24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Searchlight Pharma Inc.

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Searchlight Pharma Inc.

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-03-05

Date Granted : 2010-07-06

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2469702

Filing Date : 2002-03-05

Strength per Unit : 7.5 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-03-05

Date Granted : 2010-07-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Searchlight Pharma Inc.

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Searchlight Pharma Inc.

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-03-17

Date Granted : 2011-05-31

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2480287

Filing Date : 2003-03-17

Strength per Unit : 7.5 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-03-17

Date Granted : 2011-05-31

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Searchlight Pharma Inc.

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Searchlight Pharma Inc.

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-03-05

Date Granted : 2010-07-06

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2469702

Filing Date : 2002-03-05

Strength per Unit : 15 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-03-05

Date Granted : 2010-07-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Searchlight Pharma Inc.

Darifenacin Hydrobromide

Pharmaconex

Not Confirmed

Searchlight Pharma Inc.

Canada

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-03-17

Date Granted : 2011-05-31

Darifenacin Hydrobromide

Brand Name : ENABLEX

Patent Number : 2480287

Filing Date : 2003-03-17

Strength per Unit : 15 mg

Dosage Form : Extended Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-03-17

Date Granted : 2011-05-31

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!